Abstract
Objective
Due to the high postoperative recurrence rate in eosinophilic chronic rhinosinusitis
(eCRS) patients, there is a need for an index to predict the postoperative outcomes.
Group 2 innate lymphoid cells (ILC2s) are important effector cells for type 2 immune
responses in eosinophilic airway inflammation. The aim of this study was to investigate
whether the prevalence of ILC2s in sinonasal tissues or in peripheral blood is associated
with the postoperative outcome in CRS patients.
Methods
Twelve patients with eCRS and ten patients with non-eCRS were recruited. We examined
the ILC2 prevalence in sinonasal tissues and in peripheral blood before and after
endoscopic sinus surgery (ESS). Pre- and postoperative blood eosinophil counts were
also examined. Lund-Mackay computed tomography (LMK-CT) scores were used to evaluate
the disease severities and the postoperative outcomes; cases with more than 50% improvement
were categorized into the good outcome group, and cases with less than 50% improvement
were categorized into the poor outcome group.
Results
The ILC2 prevalence in sinonasal tissues was correlated with that in preoperative
blood in eCRS and non-eCRS patients. The ILC2 prevalence in sinonasal tissues and
in preoperative blood was not correlated with the pre- or postoperative LMK-CT scores.
Postoperatively, the ILC2 prevalence in blood was decreased in eCRS and non-eCRS patients,
and blood eosinophil count was also decreased in eCRS patients but not in non-eCRS
patients. The ILC2 prevalence in postoperative blood was decreased in the good outcome
group but not in the poor outcome group. Blood eosinophil counts were not decreased
postoperatively in both good and poor outcome groups.
Conclusion
The decreased ILC2 prevalence in postoperative blood may be a predictive biomarker
for evaluating postoperative outcomes in eCRS and non-eCRS patients.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Auris Nasus LarynxAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- European Position Paper on Rhinosinusitis and Nasal Polyps 2020.Rhinology. 2020; 58 (Suppl): 1-464
- Eosinophilic chronic rhinosinusitis.Allergol Int. 2019; 68: 403-412
- Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease.J Allergy Clin Immunol. 2008; 122: 961-968
- Pathogenesis of nasal polyposis.Clin Exp Allergy. 2015; 45: 328-346
- Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study.Allergy. 2015; 70: 995-1003
- Staging in rhinosinusitus.Rhinology. 1993; 31: 183-184
- Clustering of chronic rhinosinusitis symptomatology reveals novel associations with objective clinical and demographic characteristics.Am J Rhinol Allergy. 2015; 29: 100-105
- Past, present and future of macrolide thrapy for chronic rhinosinusitis in Japan.Auris Nasus Larynx. 2016; 43: 131-136
- Immunopathogenesis of chronic rhinosinusitis and nasal polyposis.Annu Rev Pathol. 2017; 12: 331-357
- Group 2 innate lymphoid cells and eosinophilic chronic rhinosinusitis.Curr Opin Allergy Clin Immunol. 2019; 19: 18-25
- Group 2 innate lymphoid cells are increased in nasal polyps in patients with eosinophilic chronic rhinosinusitis.Clin Immunol. 2016; 170: 1-8
- Evidence for the induction of Th2 inflammation by group 2 innate lymphoid cells in response to prostaglandin D2 and cysteinyl leukotrienes in allergic rhinisits.Allergy. 2019; 74: 2417-2426
- Group 2 innate lymphoid cells (ILC2s) are increased in chronic rhinosinusitis with nasal polyps or eosinophilia.Clin Exp Allergy. 2015; 45: 394-403
- Increased ILC2s in the eosinophilic nasal polyp endotype are associated with corticosteroid responsiveness.Clin Immunol. 2014; 155: 126-135
- Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.J Allergy Clin Immunol. 2017; 140 (e3): 101-108
- Activation of group 2 innate lymphoid cells after allergen challenge in asthmatic patients.J Allergy Clin Immunol. 2019; 144: 61-69
- Increased innate type 2 immune response in house dust mite-allergic patients with allergic rhinitis.Clinical Immunol. 2017; 183: 293-299
- Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy.J Allergy Clin Immunol. 2014; 134 (e4): 1193-1195
- Enhanced innate type 2 immune response in peripheral blood from patients with asthma.J Allergy Clin Immunol. 2014; 134: 671-678
- IL-13+ Type 2 Innate Lymphoid Cells Correlate with Asthma Control Status and Treatment Response.Am J Respir Cell Mol Biol. 2016; 55: 675-683
- Type 2 innate lymphoid cells: A novel biomarker of eosinophilic airway inflammation in patients with mild to moderate asthma.Respir Med. 2015; 109: 1391-1396
- β2 integrins rather than β1 integrins mediate Alternaria-induced group 2 innate lymphoid cell trafficking to the lung.J Allergy Clin Immunol. 2018; 141: 329-338
- Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polyps.Immun Inflamm Dis. 2017; 5: 233-243
- Adult chronic rhinosinusitis.Nat Rev Dis Primers. 2020; 6: 86
- Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status.Allergy. 2022; 77: 186-196
Article info
Publication history
Published online: December 02, 2022
Accepted:
November 21,
2022
Received:
June 17,
2022
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2022 Japanese Society of Otorhinolaryngology-Head and Neck Surgery, Inc. Published by Elsevier B.V. All rights reserved.
